investing in pharma


JNJ, BioCrossroads invest in Hoosier pharma startup at work on potential hepatitis B cure

An Indiana University spinout attracted investors from Johnson & Johnson Development Corp. and BioCrossroads with novel drugs to treat, and even potentially cure, patients with hepatitis B. Assembly Pharmaceuticals received an undisclosed amount for this seed round. This funding will finance the preclinical proof of concept and help the company establish its bio labs in San Francisco, […]